Welcome to our dedicated page for Incyte SEC filings (Ticker: INCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Incyte Genomics Inc (INCY) SEC filings page on Stock Titan aggregates regulatory documents for Incyte Corporation, a global biopharmaceutical company focused on Oncology and Inflammation & Autoimmunity. These filings provide structured insight into how the company reports its financial condition, governance changes and material events to the U.S. Securities and Exchange Commission.
Incyte’s common stock is listed on The Nasdaq Stock Market LLC under the symbol INCY, as disclosed in Form 8‑K reports. Investors can review current reports on Form 8‑K that cover topics such as quarterly financial results, executive and board transitions, inducement equity awards and key corporate agreements. For example, recent 8‑Ks describe leadership changes in the chief executive officer and chief financial officer roles, transition and employment agreements, and announcements of quarterly earnings press releases.
Alongside 8‑Ks, users can access Incyte’s annual reports on Form 10‑K and quarterly reports on Form 10‑Q (when available in the feed) to understand segment focus, risk factors, research and development priorities, and other disclosures that frame the company’s oncology and immunology strategy. These periodic reports typically detail the status of marketed products and pipeline programs, capital structure and significant accounting policies.
For those tracking management incentives and ownership, the filings page also links to insider transaction reports on Form 4 and related beneficial ownership disclosures, where present in EDGAR. These documents show grants of stock options, restricted stock units and performance shares, such as inducement awards and executive compensation packages referenced in Incyte’s current reports.
Stock Titan enhances this information by providing AI-powered summaries that explain the key points of lengthy filings, highlight notable changes and help readers interpret complex legal and financial language. Real‑time updates from EDGAR ensure that new INCY filings—whether earnings‑related, governance‑related or tied to material clinical and commercial developments—are quickly reflected, allowing investors, researchers and other stakeholders to review the underlying documents and AI insights in one place.
On 26 June 2025, Incyte Corporation (NASDAQ: INCY) filed a Form 4 reporting an insider transaction by Chief Executive Officer and Director William Meury. The filing discloses a grant of 110,630 employee stock options with an exercise price of $70.81 per share. The options vest 25 % after one year, with the remaining 75 % vesting in equal monthly installments over the subsequent three years, and expire on 25 June 2035. After this grant, Meury beneficially owns 110,630 derivative securities, held directly. No purchases or sales of common stock were reported, and the transaction is classified as "A" (acquisition). The document was signed on 30 June 2025.
In its Form 8-K dated June 26, 2025, Incyte Corporation (INCY) disclosed a major leadership transition.
Retirement of CEO Hervé Hoppenot: Mr. Hoppenot stepped down as President & Chief Executive Officer effective June 26, 2025, but will remain on the Board and act as special advisor for up to one year. Compensation during the advisory period equals his current $1,395,731 annual base salary for six months and 50% of that rate for the subsequent six months, plus a prorated 2025 cash bonus. He also received equity grants of 6,016 RSUs, 18,438 stock options, and 18,050 performance shares (0-200% payout, 3-year TSR goals), all of which will continue to vest post-transition, subject to customary covenants.
Appointment of William J. Meury as President & CEO: Effective the same date, Mr. Meury (age 57) joins the company and its Board. His background includes CEO roles at Anthos Therapeutics (2024-2025) and Karuna Therapeutics (2023-2024), senior commercial leadership at Allergan, and over 30 years in biopharma commercialization.
Compensation package for Mr. Meury: • Initial base salary $1,250,000 • Target annual bonus 100% of salary (pro-rated for 2025) • Time-based RSUs for 36,101 shares (25% per year over four years) • Options for 110,630 shares (25% after one year, then monthly over 36 months) • 108,303 performance shares (0-200% payout, 3-year TSR goals) • One-time sign-on PSU award for 125,000 shares (0-400% payout tied to multi-year stock-price hurdles) • Relocation and commuting benefits. Severance terms include 1.5× salary+target bonus if terminated without Cause or he resigns for Good Reason outside a change-of-control window, plus partial accelerated vesting of equity.
Governance changes: Lead Independent Director Julian C. Baker becomes Chairman of the Board.
These actions signal a planned but material shift in senior leadership, accompanied by significant equity-based incentives designed to align the incoming CEO with long-term shareholder value.
FAQ
What is the current stock price of Incyte (INCY)?
What is the market cap of Incyte (INCY)?
